v3.26.1
Stockholders’ equity (Tables)
6 Months Ended
Jun. 30, 2026
Schedule of Stock Option Activity

The following table summarizes the stock option activity:

  

   Shares  

Weighted-

Average

Exercise

Price

  

Weighted-

Average

Remaining

Contractual

Term (Years)

 
Outstanding at January 1, 2026   -   $-    - 
Granted   1,120,000   $1.14      
Outstanding at June 30, 2026   1,120,000   $1.14    9.3 
Exercisable at June 30, 2026   228,958   $1.14    9.3 
Schedule of Grant Date Fair Value of Each Stock Option Following Weighted-average Assumptions

The grant date fair value of each stock option grant in 2026 was estimated using the Black-Scholes option-pricing model using the following weighted-average assumptions:

  

   Six Months Ended 
   June 30, 
   2026 
Expected volatility   54.9%
Expected dividends   0.0%
Expected term   6.6 
Risk-free rate   3.9%
Exercise price  $1.14 
Schedule of stock-based Compensation Expenses

The Company recorded stock-based compensation expense (for both restricted awards and stock options) in its accompanying unaudited condensed consolidated statements of operations as follows:

 

   2026   2025   2026   2025 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2026   2025   2026   2025 
General and administrative  $90,345   $155,000   $235,080   $166,667 
Research and development   10,183    -    20,926    - 
Total stock-based compensation expense  $100,528   $155,000   $256,006   $166,667 
Consultants [Member]  
Schedule of Unvested Restricted Stock

    

   Consultant Shares   Weighted Average Grant Date Fair Value 
Unvested at December 31, 2025   258,334   $1.14000 
Granted   150,000   $1.14000 
Unvested at June 30, 2026   408,334   $1.14000